Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
23 search results for:

Niraparib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-03-2023 | EMA | News | Article
    approvalsWatch

    EMA backs niraparib–abiraterone dual-action tablet for mCRPC

    Akeega will be available in tablet form in fixed-dose combinations of niraparib 50 mg plus abiraterone 500 mg or niraparib 100 mg plus abiraterone 1000 mg, and should be given alongside prednisone or prednisolone. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group

    Author:
    Shreeya Nanda
  2. 18-02-2022 | ASCO GU 2022 | Conference coverage | Article

    Adding niraparib to abiraterone boosts mutated mCRPC outcomes

    Men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations could benefit from the addition of niraparib to first-line abiraterone acetate plus prednisone, suggest phase 3 trial data.

    Author:
    Shreeya Nanda
    Published in:
    ASCO Genitourinary Cancers Symposium; San Francisco, California, USA: 17–19 February 2022
  3. 19-02-2022 | ASCO GU 2022 | Conference coverage | Article

    Maintenance niraparib fails to improve advanced urothelial cancer PFS

    The Meet-URO12 trial of maintenance niraparib in advanced urothelial cancer patients without progression after first-line chemotherapy has failed to meet its primary endpoint of improvement in progression-free survival.

    Author:
    Shreeya Nanda
    Published in:
    ASCO Genitourinary Cancers Symposium; San Francisco, California, USA: 17–19 February 2022
  4. play
    23-02-2022 | ASCO GU 2022 | Conference coverage | Video

    MAGNITUDE shows benefit of add-on niraparib for mutated mCRPC

    Gerhardt Attard tells us why he is excited about the results of the MAGNITUDE trial evaluating the upfront addition of niraparib to abiraterone acetate in men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

  5. 10-02-2022 | Prostate cancer | News | Article

    Niraparib promising in patients with mCRPC and DNA repair gene defects

    Niraparib has antitumor activity and manageable toxicity in men with pretreated metastatic castration-resistant prostate cancer and DNA repair gene defects, shows a phase 2 trial.

    Author:
    Shreeya Nanda
    Published in:
    Lancet Oncol 2022; doi:10.1016/ S1470-2045(21)00757-9
  6. 03-10-2017 | EMA | News | Article
    approvalsWatch

    Niraparib, padeliporfin receive EMA nod

    medwireNews : The European Medicines Agency (EMA) has recommended that a marketing authorization be granted to niraparib and padeliporfin for the treatment of ovarian cancer and adenocarcinoma of the prostate, respectively.

  7. 18-10-2016 | Ovarian cancer | News | Article
    Editor's pick

    Niraparib maintenance ‘warranted’ for platinum-sensitive recurrent ovarian cancer

    ENGOT-OV16/NOVA trial results support the use of maintenance treatment with niraparib for platinum-sensitive recurrent ovarian cancer, in both patients with and without a germline BRCA mutation.

    Published in:
    N Engl J Med 2016; Advance online publication;  ESMO 2016; Copenhagen, Denmark

  8. Niraparib maintenance ‘warranted’ for platinum-sensitive recurrent ovarian cancer

    medwireNews: ENGOT-OV16/NOVA trial results support the use of maintenance treatment with niraparib for platinum-sensitive recurrent ovarian cancer, in both patients with and without a germline (g)BRCA ...

  9. play
    22-02-2022 | ASCO GU 2022 | Conference coverage | Video

    Add-on PARP inhibition in metastatic CRPC: PROpel and MAGNITUDE

    David VanderWeele comments on the PROpel and MAGNITUDE trials investigating the addition of a PARP inhibitor to abiraterone in men with metastatic castration-resistant prostate cancer, focusing on the differences between the studies and the unanswered questions.

  10. 22-10-2021 | PARP inhibitors | News | Article

    Pancytopenia risk demonstrated for PARP inhibitor use

    This translated to a significant association between PARP inhibitor use and pancytopenia for the drug class as a whole (reporting odds ratio [ROR]=5.5) and for the five individual PARP inhibitors assessed, namely talazoparib (ROR=17.4), veliparib (ROR=8.2), niraparib (ROR=6.8), olaparib (ROR=5.3), and rucaparib (ROR=2.2).

    Author:
    Lynda Williams
    Published in:
    JAMA Oncol 2021; doi:10.1001/jamaoncol.2021.4672 JAMA Oncol 2021; doi:10.1001/jamaoncol.2021.4639 JAMA Oncol 2021; doi:10.1001/jamaoncol.2021.4664
  11. 04-09-2020 | Prostate cancer | News | Article

    Rucaparib has ‘meaningful’ antitumor activity in BRCA-mutated mCRPC

    “Our results are consistent with those from other studies demonstrating the clinical activity of PARP inhibitors (olaparib, niraparib, and talazoparib) in patients with mCRPC and a BRCA alteration who received prior AR-directed therapy,” say Abida and colleagues.

    Author:
    Hannah Kitt
    Published in:
    J Clin Oncol 2020; doi:10.1200/JCO.20.01035
  12. 31-03-2017 | PARP inhibitors | News | Article
    approvalsWatch

    FDA approvals announced for PARP inhibitor, EGFR T790M-targeted agent

    Niraparib was granted fast-track, priority review and breakthrough therapy status following trial results showing improved progression-free survival compared with placebo in patients with and without a germline BRCA mutation.

  13. 07-09-2017 | Ovarian cancer | Article

    Bringing new medicines to women with epithelial ovarian cancer: What is the unmet medical need?

    Herzog TJ, Monk BJ. Gynaecol Oncol Res Pract 2017;4:13. doi:10.1186/s40661-017-0050-0

  14. 28-07-2017 | PARP inhibitors | Article

    PARP inhibitors in breast cancer: Latest evidence

    This paper reviews the results of clinical trials of the poly(ADP-ribose) polymerase-1 (PARP1) inhibitors in breast cancer, as well as other important ongoing trials. Ponec RM, Peddi R, Callahan RD. Curr Breast Cancer Rep  2017;9:188–194. doi:10.1007/s12609-017-0251-x

  15. 13-12-2016 | Ovarian cancer | Article

    Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

    Nevertheless, patients without a BRCA mutation and those that were defined as HRD negative in this trial (defined using the myChoice HRD test), also derived a degree of benefit from niraparib maintenance therapy, raising a possibility of a wider application of niraparib beyond BRCA -mutated ovarian cancer 40 .

    Author:
    Angela George, Stan Kaye, Susana Banerjee
  16. 13-12-2016 | PARP inhibitors | Article

    Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

    Nevertheless, patients without a BRCA mutation and those that were defined as HRD negative in this trial (defined using the myChoice HRD test), also derived a degree of benefit from niraparib maintenance therapy, raising a possibility of a wider application of niraparib beyond BRCA -mutated ovarian cancer 40 .

    Author:
    Angela George, Stan Kaye, Susana Banerjee
  17. 13-10-2016 | PARP inhibitors | Article

    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: Current practice and future directions

    Niraparib Niraparib is under investigation in patients with and without BRCA -mutated cancer (Sandhu et al , 2013).

    Author:
    G E Konecny, R S Kristeleit
  18. 22-06-2017 | PARP inhibitors | Article

    Targeting DNA repair and replication stress in the treatment of ovarian cancer

    This review examines the rationale behind and strategies for DNA repair inhibitors and cell cycle checkpoint inhibitors, as single agent therapy and in combination with DNA damaging agents in ovarian cancer. Murai J. Int J Clin Oncol  2017;22:619–628. doi:10.1007/s10147-017-1145-7

  19. 16-03-2016 | Gynecologic cancers | Article

    What is the place of PARP inhibitors in ovarian cancer treatment?

    This review focuses on current clinical use of poly [ADP-ribose] polymerase inhibitors for the treatment of ovarian cancer and provides an overview of ongoing clinical trials. Liu JF & Matulonis UA. Curr Oncol Rep 2016; 18: 29. doi:10.1007/s11912-016-0515-z

  20. 16-03-2016 | PARP inhibitors | Article

    What is the place of PARP inhibitors in ovarian cancer treatment?

    This review summarizes clinical experience and ongoing clinical trials with the poly(ADP-ribose) polymerase-1 (PARP1) inhibitors in ovarian cancer. Liu JF, Matulonis UA. Curr Oncol Rep 2016;18:29. doi:10.1007/s11912-016-0515-z

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.